Neopharmed Gentili
- Company typePrivate
- Founded2011
- HeadquartersGottolengo, Italy
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Neopharmed Gentili firmographics
Firmographics- Name
- Neopharmed Gentili
- Legal name
- Neopharmed Gentili S.p.A.
- Website
- http://www.neogen.it
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Neopharmed Gentili industry classification
Industry- Product category
- Branded Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Neopharmed Gentili is headquartered
LocationHeadquarters
- HQ city
- Gottolengo
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Neopharmed Gentili business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Pharmaceutical Product Sales: Revenue generated from commercialization of branded pharmaceutical products across multiple therapeutic areas in Italy and Europe
- European Licensing Revenue: Upfront payments and milestone payments received from European licensing agreements, plus ongoing royalty streams from product commercialization rights
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Neopharmed Gentili product offering
Product offeringCore offering
Neopharmed Gentili commercializes high therapeutic value branded pharmaceutical products across more than ten therapeutic areas in Italy and Europe, including cardio-metabolic, vascular, pneumo-allergological, antibiotic, osteoarticular, gastro-enteric, neuro-psychiatric, otorhinolaryngological, pediatric, and urological conditions. Its portfolio combines in-house and acquired products with licensed brands such as ORLADEYO (berotralstat) and the pipeline asset navenibart for hereditary angioedema, and Plasil (metoclopramide) for gastroenterology. The company reaches patients through a field-based scientific information force, an HCP portal, and standard Italian pharmaceutical distribution channels.
Product overview
Neopharmed Gentili is an Italian pharmaceutical company specializing in the commercialization of high therapeutic value solutions across 10+ therapeutic areas including cardio-metabolic, vascular, pulmonary-allergologic, antibiotic, osteoarticular, gastroenterological, neuropsychiatry, otorhinolaryngological, pediatric, and urological conditions. The company operates a multi-brand portfolio approach, commercializing both in-house developed/acquired products and licensed brands. Key products include ORLADEYO® (berotralstat) for hereditary angioedema (acquired from BioCryst in 2025), the pipeline product Navenibart (Phase 3 for HAE), and the gastroenterology brand Plasil® (metoclopramide). The company treats over 3 million patients annually and maintains a business model combining M&A, licensing-in arrangements, and organic portfolio expansion across therapeutic areas.
Differentiator
Problem solved
Functional benefit
Products and services
- Cardio-Metabolic Portfolio
- Vascular Portfolio
- Pulmonary-Allergologic Portfolio
- Antibiotic Portfolio
- Osteoarticular Portfolio
- Gastroenterological Portfolio
- Neuropsychiatry Portfolio
- Otorhinolaryngological Portfolio
- Pediatric Portfolio
- Urological Portfolio
- ORLADEYO (berotralstat) ORLADEYO is an oral, once-daily medication for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. Neopharmed Gentili acquired the European commercial rights from BioCryst Pharmaceuticals in 2025.
- Navenibart (European rights) Navenibart is an investigational long-acting plasma kallikrein inhibitor in Phase 3 development for hereditary angioedema (HAE), for which Neopharmed Gentili acquired exclusive European commercial rights through a licensing agreement with BioCryst Pharmaceuticals.
- Plasil (metoclopramide) Plasil is a gastroenterology brand containing metoclopramide, used for gastrointestinal disorders associated with dyspepsia, nausea, and emesis. Neopharmed Gentili acquired the product in February 2025 and later licensed it to Lupin for the Philippines and Brazil markets.
Quantifiable outcome
- Over 3 million patients treated in 2024
- +1 more outcomes
Companies that use Neopharmed Gentili
Customer profileNamed customers2 records
Segments7 records
Ideal customer profiles3 records
Neopharmed Gentili technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Neopharmed Gentili partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Favillini Pharmaceutical Packaging Group SpAminorFrom 2026, Neopharmed Gentili uses FSC-certified packaging materials from Favillini Pharmaceutical Packaging Group SpA for cartons and instructional leaflets, supporting sustainability objectives with materials from responsibly managed forests.
- Lupin LimitedminorLupin granted Neopharmed exclusive licensing rights for the gastroenterology brand Plasil in the Philippines and Brazil, covering distribution rights for this肠胃品牌.
- BioCryst PharmaceuticalscoreNeopharmed Gentili acquired the European business of ORLADEYO (berotralstat) from BioCryst Pharmaceuticals for US$250 million upfront with potential additional milestone considerations. The acquisition completed in October 2025. Additionally, Neopharmed Gentili's Irish affiliate received exclusive European commercial rights to navenibart for $70 million upfront plus up to $275 million in milestones and 18-30% tiered royalties.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Neopharmed Gentili competitors and assessment
Company assessmentDirect peers
- Chiesi Farmaceutici S.p.A. Chiesi is a privately held Italian specialty pharma with strong rare disease franchises (including respiratory and HAE-adjacent areas) and European licensing partnerships, closely comparable to Neopharmed's specialty and rare disease commercialization model.
- Angelini Pharma: Angelini Pharma is a privately held Italian pharmaceutical company with a multi-therapeutic portfolio spanning CNS, pain, infectious disease and consumer health across Europe, directly comparable to Neopharmed's breadth-based specialty model.
- Recordati S.p.A. Recordati is an Italian specialty pharmaceutical group with a similar multi-therapeutic European commercial footprint and a track record of acquiring and developing branded pharmaceuticals across rare diseases, cardiology, urology, and other specialty areas, making it the closest direct peer in business model and geography.
- Zambon S.p.A. Zambon is an Italian specialty pharma with multi-therapeutic respiratory, CNS, and rare disease products across European markets, with comparable geographic footprint and commercialization-led growth model.
- Molteni Farmaceutici S.p.A. Molteni is an Italian specialty pharmaceutical company with a focus on pain, addiction, and rare disease therapeutics in European markets, sharing Neopharmed's privately held Italian specialty pharma profile.
- Dompé Farmaceutici S.p.A. Dompé is a privately held Italian biopharma with both proprietary and licensed specialty products, including rare disease ophthalmology, comparable to Neopharmed's mix of branded specialty and rare disease commercialization.
- Italfarmaco S.p.A. Italfarmaco is a privately held Italian pharma group with specialty and rare disease products sold internationally, sharing Neopharmed's profile as a mid-sized Italian specialty pharmaceutical company pursuing geographic expansion.
Broad incumbents
- Almirall S.A. Almirall is a European specialty pharmaceutical company focused on dermatology and other specialty areas with strong Southern European commercial reach, relevant as a peer for mid-sized European specialty commercialization strategies.
- Menarini Group: Menarini is a much larger privately held Italian pharmaceutical group with a broad multi-therapeutic European portfolio, providing a benchmark for an Italian pharma peer that has scaled internationally while remaining private.
- Stada Arzneimittel AG: Stada is a European specialty and generics pharma group active across multiple therapeutic areas with significant presence in Italy, comparable to Neopharmed as a broader, PE-influenced European specialty commercializer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Neopharmed Gentili social profiles
Digital presenceNeopharmed Gentili compliance and trust
Trust signalCompliance4 records
Neopharmed Gentili financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neopharmed Gentili leadership team
Management profileNumber of profiles
Profiles2 records
Neopharmed Gentili subsidiaries and ownership
Company hierarchySubsidiaries1 record
Neopharmed Gentili funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neopharmed Gentili M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neopharmed Gentili
What does Neopharmed Gentili do?
Neopharmed Gentili commercializes high therapeutic value branded pharmaceutical products across more than ten therapeutic areas in Italy and Europe, including cardio-metabolic, vascular, pneumo-allergological, antibiotic, osteoarticular, gastro-enteric, neuro-psychiatric, otorhinolaryngological, pediatric, and urological conditions. Its portfolio combines in-house and acquired products with licensed brands such as ORLADEYO (berotralstat) and the pipeline asset navenibart for hereditary angioedema, and Plasil (metoclopramide) for gastroenterology. The company reaches patients through a field-based scientific information force, an HCP portal, and standard Italian pharmaceutical distribution channels.
Is Neopharmed Gentili a public or private company?
Neopharmed Gentili is a private company. It is classified as private equity controlled and is currently operating.
When was Neopharmed Gentili founded?
Neopharmed Gentili was founded in 2011. It employs 101 to 250 people.
Where is Neopharmed Gentili based?
Neopharmed Gentili is headquartered in Gottolengo, Italy, in the Europe region.
How does Neopharmed Gentili make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are european Licensing Revenue.
Who are Neopharmed Gentili's main competitors?
Direct peers on record are Chiesi Farmaceutici S.p.A., Angelini Pharma, Recordati S.p.A., Zambon S.p.A., Molteni Farmaceutici S.p.A., Dompé Farmaceutici S.p.A. and Italfarmaco S.p.A.. Broad incumbents are Almirall S.A., Menarini Group and Stada Arzneimittel AG.
Does Neopharmed Gentili have an API?
No public API is recorded for Neopharmed Gentili.
What industry is Neopharmed Gentili in?
Neopharmed Gentili's product category is Branded Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its SIC code is 2834.